Fujisawa Micafungin Safety, Prophylatic Use Could Be Benefits Vs. Cancidas
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.